Department of Gynaecology, Leiden University Medical Center, Leiden, The Netherlands.
J Psychosom Obstet Gynaecol. 2013 Sep;34(3):129-32. doi: 10.3109/0167482X.2013.821977. Epub 2013 Aug 5.
The aim of this study was to assess oncologists' practice and attitudes regarding treatment-related infertility and fertility preservation in female cancer patients of reproductive age.
Recruitment letters with a 7-item questionnaire were sent to 454 oncologists.
Two hundred and six of the 454 physicians (45%) responded and 96 questionnaires were used for analysis. The sample included 28 (29%) gynaecologists, 22 (23%) medical oncologists, 19 (20%) surgeons, 16 (17%) radiotherapists and 11 (12%) haematologists. Sixty-two percent of the physicians took action to protect ovarian function before or during gonadotoxic therapy. The most important reason for not offering fertility preservation was "factors concerning the disease". About one-third of the oncologists did not discuss fertility issues. Nearly half of the physicians (43%) would offer fertility preservation options, if they were standardized. High importance was given by almost all physicians (96%) to quality of life in general after gonadotoxic therapy and to the provision of information about fertility preservation options (81%). However, when asked about the importance of infertility after a malignancy, a smaller majority of the physicians (59%) gave it high importance.
Most physicians considered infertility to be a major issue to be discussed, and most intended to take action to protect ovarian function before or during gonadotoxic therapy.
本研究旨在评估肿瘤科医生在治疗相关不孕和生育力保护方面的实践和态度,以及这些因素在女性生殖年龄癌症患者中的应用。
向 454 名肿瘤医生发送了征募信和一份包含 7 个问题的问卷。
454 名医生中有 206 名(45%)做出了回应,其中 96 份问卷被用于分析。样本包括 28 名妇科医生(29%)、22 名内科肿瘤医生(23%)、19 名外科医生(20%)、16 名放射肿瘤医生(17%)和 11 名血液科医生(12%)。62%的医生在性腺毒性治疗前或治疗期间采取措施保护卵巢功能。不提供生育力保护的最重要原因是“与疾病相关的因素”。约三分之一的肿瘤医生没有讨论生育问题。近一半的医生(43%)如果生育保护选项标准化,他们将提供生育保护选项。几乎所有医生(96%)都高度重视性腺毒性治疗后一般的生活质量和提供生育保护选项的信息(81%)。然而,当被问及癌症后不孕的重要性时,只有略多于一半的医生(59%)认为这是一个重要问题。
大多数医生认为不孕是一个需要讨论的主要问题,大多数医生打算在性腺毒性治疗前或治疗期间采取行动保护卵巢功能。